Clinical Trial Detail

NCT ID NCT03860987
Title Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

prostate cancer

Therapies

Abiraterone + Enzalutamide + Goserelin + Prednisone

Age Groups: adult senior

No variant requirements are available.